BioVie Inc
BIVI
NSC
Sector: Healthcare
Industry: Biotechnology
2.18
USD
-0.02
(-0.91%)
Optionable: No Market Cap: 53 M 90-day average vol: 0
Previous close: 2.2 Open: 2.33 Bid: 2.43 Ask: 2.43
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 0.00 |
Price per Book TTM ($) | 5.23 |
PE Ratio (TTM) | -0.20 |
Book Value per Share ($) | 0.40 |
5 Year PE Range | -12.7 , -1.2 |
Returns
7 Day Return | 4.31% | |
1 Month Return | 21.11% | |
3 Month Return | -28.52% | |
1 Year Return | -75.78% | |
3 Year Return | -65.53% | |
5 Year Return | -65.53% | |
YTD Return | -51.56% |
Risk
Custom Beta One Year | 0.92 |
Custom Beta Three Years | 0.96 |
Beneish M Score | 0.00 |
Altman Z Score | -92.41 |
Financial Health
Technicals
RSI (14 Day) | 55.53 |
14 Day SMA ($) | 2.16 |
14 Day EMA ($) | 2.12 |
Money Flow Index | 14.88 |
Average True Range | 0.18 |
50 Day SMA ($) | 1.94 |
200 Day SMA ($) | 3.79 |
ADX | 19.20 |
MACD | 0.07 |
Growth
Free Cash Flow QoQ Growth | 25.04% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 27.27% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
Yahoo Finance 1/20/2022
Has Biocept, Inc. (BIOC) Outpaced Other Medical Stocks This Year?
Yahoo Finance 1/7/2022
BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event
Yahoo Finance 12/28/2021
BioVie Announces Partnership with the American Liver Foundation
Yahoo Finance 12/9/2021
BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.
Yahoo Finance 12/1/2021
BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update
Yahoo Finance 11/4/2021
BioVie Announces the Appointment of a New Chief Medical Officer
Yahoo Finance 11/1/2021
BioVie rises 21% on FDA nod to start phase 2 trial of NE3107 in Parkinson’s Disease
Seeking Alpha 10/26/2021
BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
Yahoo Finance 10/26/2021
BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease
Yahoo Finance 10/13/2021
BioVie to Present at Cantor Virtual Global Healthcare Conference
Yahoo Finance 9/22/2021
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
Yahoo Finance 9/15/2021
BioVie Inc. Announces Closing of Public Offering of Common Stock
Yahoo Finance 8/11/2021
BioVie plunges 37% after pricing equity raise
Seeking Alpha 8/9/2021
BioVie secures $20M via equity raise
Seeking Alpha 8/8/2021
BioVie Inc. Announces Pricing of Public Offering of Common Stock
Yahoo Finance 8/9/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 3.648
Financials
BIVI Income Statement
Annual
| Invalid date | Jun-13 | Jun-14 | Jun-15 | Jun-16 | Jun-17 | Jun-18 | Jun-19 | Jun-20 | Jun-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of sales | 0 | -2589 | -7500 | -55947 | -229377 | -229377 | -229377 | -229377 | -229377 | |
| Gross operating profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling Gen & administrative expense | 17515 | 272966 | 229181 | 343091 | 857883 | 2 M | 1 M | 1 M | 5 M | |
| Research & development expense | 0 | 49419 | 4196 | 37901 | 466354 | 370852 | 1 M | 1 M | 133 M | |
| Operating income | -17515 | -322385 | -233377 | -432028 | -2 M | -2 M | -2 M | -3 M | -138 M | |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other income net | 0 | 0 | 0 | 0 | 222928 | 0 | 51400 | -9 M | 8 M | |
| Pre-tax Income (EBT) | -17510 | -321896 | -233008 | -431923 | -1 M | -2 M | -2 M | -17 M | -130 M | |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income from total operations | -17510 | -321896 | -233008 | -431923 | -1 M | -2 M | -2 M | -17 M | -130 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total net income | -17510 | -321896 | -233008 | -431923 | -1 M | -2 M | -2 M | -17 M | -130 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Net income available for common | -17510 | -321896 | -233008 | -431923 | -1 M | -2 M | -2 M | -17 M | -130 M | |
| Depreciation | 0 | 2589 | 7500 | 55947 | 229377 | 229377 | 229377 | 229377 | 229377 | |
| Amortization | 0 | 0 | 0 | 51036 | 229377 | 229377 | 229377 | 229377 | 229377 | |
| Operating income before depreciation (EBITDA) | -17510 | -321896 | -233377 | -380806 | -1 M | -2 M | -2 M | -12 M | -129 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.05 | -0.46 | -0.33 | -0.62 | -1.25 | -3.75 | -0.98 | -6.85 | -14.82 | |
| Diluted EPS total | -0.05 | -0.46 | -0.33 | -0.62 | -1.25 | -3.75 | -0.98 | -6.85 | -14.82 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!